C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 (PAR2), Displays in vivo Efficacy Against Protease-Induced Pain in Mice

Given the limited options and often harmful side effects of current analgesics and the suffering caused by the opioid crisis, new classes of pain therapeutics are needed. Protease-activated receptors (PARs), particularly PAR2, are implicated in a variety of pathologies, including pain. Since the dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kume, Moeno, Ahmad, Ayesha, Shiers, Stephanie, Burton, Michael D., DeFea, Kathryn A., Vagner, Josef, Dussor, Gregory, Boitano, Scott, Price, Theodore J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079573/
https://www.ncbi.nlm.nih.gov/pubmed/36417966
http://dx.doi.org/10.1016/j.jpain.2022.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079573/
https://www.ncbi.nlm.nih.gov/pubmed/36417966
http://dx.doi.org/10.1016/j.jpain.2022.11.006

Ejemplares similares